Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers

Clinical Cancer Research

Volumn 13, Issue 20, 2007, Pages 6187-6194

  Plummer, Ruth ^a,d   Attard, Gerhardt ^b   Pacey, Simon ^b   Li, Louise ^a   Razak, Albiruni ^a   Perrett, Rebecca ^a   Barrett, Mary ^b   Judson, Ian ^b   Kaye, Stan ^b   Fox, Norma Lynn ^c   Halpern, Wendy ^c   Corey, Alfred ^c   Calvert, Hilary ^a   De Bono, Johann ^b  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

^c GLAXOSMITHKLINE   (United States)

^d NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CIPROFLOXACIN; CISPLATIN; DEATH RECEPTOR 5; DOCETAXEL; LEXATUMUMAB; MAPATUMUMAB; MONOCLONAL ANTIBODY; OBLIMERSEN; PACLITAXEL; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; AMYLASE BLOOD LEVEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACKACHE; BILE DUCT CARCINOMA; BILIRUBIN BLOOD LEVEL; BLADDER CARCINOMA; BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CARCINOMA; CONSTIPATION; COUGHING; CREATININE BLOOD LEVEL; DIARRHEA; DIZZINESS; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; DYSPNEA; ENDOMETRIUM CARCINOMA; ESOPHAGUS CARCINOMA; FATIGUE; FEMALE; FEVER; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEAD AND NECK CANCER; HEADACHE; HUMAN; HUMAN TISSUE; HYPERBILIRUBINEMIA; IMMUNOGENICITY; IMMUNOHISTOCHEMISTRY; LETHARGY; LIMB PAIN; LIVER CARCINOMA; LOWER RESPIRATORY TRACT INFECTION; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; OPEN STUDY; OSTEOSARCOMA; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; SARCOMA; SHOULDER PAIN; SIDE EFFECT; SKIN CARCINOMA; SOFT TISSUE SARCOMA; SOLID TUMOR; THYMOMA; URINARY TRACT INFECTION; VOMITING;

ADULT; AGED; ANTIBODIES, MONOCLONAL; AREA UNDER CURVE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 35948952826     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-0950     Document Type: Article

References (31)

1. Humphreys R. Development and evaluation of cancer therapeutics agents targeting TRAIL receptor 1 and 2. The oncogenomics handbook: Humana Press Inc; 2005. p. 659-76.
2. Bouralexis S, Findlay DM, Evdokiou A. Death to the bad guys: targeting cancer via Apo2L/TRAIL. Apoptosis 2005;10:35-51.
3. Igney FH, Krammer PH. Tumour resistance to apoptosis. Nat Rev Cancer 2002;2:277-88.
4. Spierings DCJ, De Vries EG, Timens W, Groen H, Boezen H, deJong S. Expression of TRAIL and TRAIL death receptors in stage III non-small cell lung cancer tumours. Clin Cancer Res 2003;9:3397-405.
5. Koornstra JJ, Jalving M, Rijcken FEM, et al. Expression of tumour necrosis factor-related apoptosis-inducing ligand death receptors in sporadic and hereditary colorectal tumours: potential targets for apoptosis induction. Eur J Cancer 2005;41:1195-202.
6. Daniels RA, Turley H, Kimberley FC, et al. Expression of TRAIL and TRAIL receptors in normal and malignant tissues. Cell Res 2005;15:430-8.
7. McCarthy MM, Sznol M, DiVito KA, Camp RL, Rimm DL, Kluger HM. Evaluating the expression and prognostic value of TRAIL-R1 and TRAIL-R2 in breast cancer. Clin Cancer Res 2005;11:5188-94.
8. Spierings DCJ, De Vries EG, Vellenga E, et al. Tissue distribution of the death ligand TRAIL and its receptors. J Histochem Cytochem 2004;52:821-31.
9. Gong J, Yang D, Kohanim S, Humphreys R, Broemeling L, Kurzrock R. Novel in vivo imaging shows upregulation of death receptors by paclitaxel and correlates with enhanced antitumor effects of receptor agonist antibodies. Mol Cancer Ther 2006; 5:2991-3000.
10. Humphreys RC, Alderson RF, Bayever E, et al. TRAIL R2-mAb, a human agonistic monoclonal antibody to tumor necrosis factor-related apoptosis inducing ligand receptor 2, affects tumor growth and induces apoptosis in human tumor xenograft models in vivo. 94th AACR Annual Meeting 2003; 44:642.
11. Alderson RF, Birse CE, Connolly K, et al. TRAIL-R2 mAb, a human agonistic monoclonal antibody to tumor necrosis factor-related apoptosis inducing ligand receptor 2, induces apoptosis in human tumor cells. Proceedings of 94th AACR Annual Meeting 2003; 44:963.
12. Zeng Y, Wu XX, Fiscella M, et al. Monoclonal antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2 (TRAIL-R2) induces apoptosis in primary renal cell carcinoma cells in vitro and inhibits tumor growth in vivo. Int J Oncol 2006; 28:421-30.
13. Georgakis GV, Li Y, Humphreys R, et al. Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death. Br J Haematol 2005; 130:501-10.
14. Gillotte D, Johnson RL, Poortman C, et al. Human agonistic anti-TRAIL receptor antibodies, HGS-ETR1 and HGS-ETR2, induce apoptosis in ovarian tumor lines and their activity is enhanced by taxol and carboplatin. Proceedings of the AACR 2004;45.
15. Humphreys R, Shepard L, Poortman C, Carroll J, Albert V. HGS-ETR2, an agonistic, TRAIL receptor 2 human monoclonal antibody, synergizes with chemotherapeutic agents to increase in vitro cytotoxicity and induce tumor regression in vivo tumor xenografts. Clin Cancer Res (Supl) 2005;11:133.
16. Pacey S, Plummer RE, Attard G, et al. Phase I and pharmacokinetic study of HGS-ETR2, a human monoclonal antibody to TRAIL R2, in patients with advanced solid malignancies. J Clin Oncol 2005;23: 205S-S.
17. Attard G, Plummer RE, De Bono JS, et al. Phase I and pharmacokinetic study of HGS-ETR2, a fully human agonistic monoclonal antibody to TRAIL-R2, in patients with advanced solid malignancies. Clin Cancer Res 2005;11:9060S-S.
18. Scher HI, Eisenberger M, D'Amico AV, et al. Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 2004; 22:537-56.
19. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumours. J Natl Cancer Inst 2000;92: 205-16.
20. Rowinsky EK. Targeted induction of apoptosis in cancer management: the emerging role of tumor necrosis factor-related apoptosis-inducing ligand receptor activating agents. J Clin Oncol 2005;23: 9394-407.
21. Halpern W, Lincoln C, Roach A. TRAIL receptor 2 protein expression in normal and tumour tissue [abstract 83 p]. Ann Oncol 2004;15:22.
22. Tolcher AW, Mita M, Patnaik A, et al. A phase I and pharmacokinetic study of HGS-ETR1 (TRM-1), a human monoclonal agonist-antibody to TRAIL R1, in patients with advanced solid tumors [abstract]. J Clin Oncol 2004;22:210S.
23. Sarantopoulos J, Wakelee H, Mita M, et al. HGS-ETR2-ST02: a phase 1 clinical trial of HGS-ETR2, a fully-human activating monoclonal antibody to TRAIL-R2, in patients with advanced solid tumors [abstract]. Clin Cancer Res 2005;11:9104S.
24. Younes A, Vose JM, Zelenetz AD, et al. Results of a phase 2 trial of HGS-ETR1 (agonistic human monoclonal antibody to TRAIL receptor 1) in subjects with relapsed/refractory non-Hodgkin's lymphoma (NHL). Blood 2005;106:146-7A.
25. Bonomi P, Greco F, Crawford J, Kelly K, Oh Y, Klein J. Results of a phase 2 trial of HGS-ETR1 (agonistic human monoclonal antibody to TRAIL receptor 1) in subjects with relapsed/recurrent non-small cell lung cancer (NSCLC) [abstract]. Lung Cancer 2005;49:S238.
26. Marini P, Denzinger S, Kauder S, et al. In vitro and in vivo effects after combined treatment of colorectal tumors with apoptosis inducing trail receptor antibodies HGS-ETR1 and HGS-ETR2 and radiotherapy [abstract]. Radiother Oncol 2006;78:S75.
27. Hariharan S, Gore L, Eckhardt S, et al. A phase I and pharmacological study of HGS-ETR1, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies. Clin Cancer Res 2005;11: 9058-9S.
28. Mom CH, Sleijfer S, Gietema JA, et al. A phase 1 study of HGS-ETR1, a fully human agonistic monoclonal antibody to the TRAIL-R1, in combination with gemcitabine and cisplatin in subjects with advanced solid malignancies. Clin Cancer Res 2005; 11:9117S-S.
29. Mendolson D, Ebbinghaus S, Gordon M, et al. A phase I safety and pharmacokinetic (PK) study of recombinant Apo2L/TRAIL, an apoptosis-inducing protein in patients with advanced cancer [abstract]. J Clin Oncol 2006;24:124s.
30. Patnaik A, Wakelee H, Mita M, et al. HGS-ETR2 - a fully human monoclonal antibody to TRAIL-R2: Results of a phase I trial in patients with advanced tumours [abstract]. J Clin Oncol 2006;24:123s.
31. Pukac L, Kanakaraj P, Humphreys R. HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo. Br J Cancer 2005;92:1430-41.